Hengrui Medicine gets approval for prostate cancer drug trials

Jiangsu Hengrui Medicine and subsidiary Chengdu Shengdi Pharmaceutical received approval from the National Medical Products Administration to conduct clinical trials for HRS-5041 tablets, a prostate cancer treatment.

The drug demonstrates significant degradation of AR protein in both wild-type and mutated forms, potentially overcoming drug resistance compared to second-generation AR inhibitors. No similar products are approved domestically or internationally.

Cumulative research and development investment for the project stands at approximately 69.19 million yuan.